From The Motley Fool · Adria Cimino · · 1m
Moderna Stock Surges Past AI Giants
Moderna's stock has crushed Nvidia, Micron, and Sandisk with 600% gains this year, now in Nasdaq-100.
In brief
Moderna's stock has crushed Nvidia, Micron, and Sandisk with 600% gains this year, now in Nasdaq-100. Moderna's stock surged over 600% this year, surpassing AI stocks and Wall Street price targets as it advances into oncology treatments. Originally reported by The Motley Fool.
Moderna's 600% surge
Moderna's stock surged over 600% this year, outperforming Nvidia, Micron, and Sandisk.
Nasdaq-100 entry
Moderna entered the Nasdaq-100 index this year, tracking the biggest non-financial Nasdaq companies.
Coronavirus vaccine success
Moderna's coronavirus vaccine generated over $18 billion in revenue at its peak in 2022.
Recent challenges
Moderna faced declining vaccine demand, RSV vaccine struggles, and a failed CMV vaccine candidate.
Oncology breakthrough
Moderna's intismeran autogene vaccine showed success in melanoma patients with recurrence-free survival.
Price target surpassing
Moderna's stock price of $225 surpasses Wall Street's average 12-month price estimate of $122.
Buy recommendation
Moderna has room to grow as it wins approval for oncology treatments and generates new revenue streams.
“Moderna is transforming into a larger biotech company with the ability to address a broad range of treatment areas.”
The bottom line
Moderna's stock surged over 600% this year, surpassing AI stocks and Wall Street price targets as it advances into oncology treatments.
